Reynold C. Ly
Pharmacology, Toxicology and Pharmaceutics · Indiana University
Publications
47
Citations
691
Est. group size
—
Recurring co-author estimate
Active years
17
Publishing since 2010
Reynold C. Ly studies pharmacogenetics drug metabolism developing recommendations for how genetic testing should guide drug prescribing. Much of the work focuses on laboratory standards for genotyping genes that affect how patients respond to medications (such as CYP2D6, DPYD, TPMT, and warfarin-related genes), along with related research in cancer biology and metabolism. The work spans clinical diagnostics, genetic sequencing methods, and personalized medicine.
Publication activity grew notably from 2019 onward, peaking around 2022-2023, with a more variable output in the most recent years.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~11 · 10% small-team papers (≤3 authors) · across 11 venues
- P598: Clinical diagnostic utility of exome sequencing reanalysis and genome sequencing In a pediatric cohort with undiagnosed genetic disease
Genetics in Medicine Open · 2026
- Reduction of next-generation sequencing files for efficient pharmacogenotype extraction
Figshare · 2026
- Reduction of next-generation sequencing files for efficient pharmacogenotype extraction
Pharmacogenomics · 2026
- Reduction of next-generation sequencing files for efficient pharmacogenotype extraction
Figshare · 2026
- Commentary on An Ambiguous <i>NUDT15</i> Signal in a Child with B-Cell Acute Lymphoblastic Leukemia
Clinical Chemistry · 2025
- DPYD Genotyping Recommendations
Journal of Molecular Diagnostics · 2024
- Education of Future Pharmacogenomics Laboratory Directors
Advances in Molecular Pathology · 2024
- CYP3A4 and CYP3A5 Genotyping Recommendations
Journal of Molecular Diagnostics · 2023
- PharmVar Tutorial on <i>CYP2D6</i> Structural Variation Testing and Recommendations on Reporting
Clinical Pharmacology & Therapeutics · 2023
- Characterization of Reference Materials for CYP3A4 and CYP3A5
Journal of Molecular Diagnostics · 2023
- TPMT and NUDT15 Genotyping Recommendations: A Joint Consensus Recommendation of the Association for Molecular Pathology, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, and Pharmacogenomics Knowledgebase
Journal of Molecular Diagnostics · 2022
- Table of Contents
Journal of Molecular Diagnostics · 2022
- Pharmacokinetic modeling of R and S‐Methadone and their metabolites to study the effects of various covariates in post‐operative children
CPT Pharmacometrics & Systems Pharmacology · 2021
- Recommendations for Clinical CYP2D6 Genotyping Allele Selection
Journal of Molecular Diagnostics · 2021
- Recommendations for Clinical Warfarin Genotyping Allele Selection
Journal of Molecular Diagnostics · 2020
- Journal of Molecular Diagnostics×8
- Figshare×4
- Genetics in Medicine Open×3
- Clinical Pharmacology & Therapeutics×2
- JCO Precision Oncology×2
- Daniel L. Hertz
Medicine · University of Michigan
- Amy L. Pasternak
Pharmacology, Toxicology and Pharmaceutics · University of Michigan
- Tyler Shugg
Pharmacology, Toxicology and Pharmaceutics · Indiana University
- Gloria Xue
Medicine · Indiana University
- Aditi Shendre
Pharmacology, Toxicology and Pharmaceutics · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 27, 2026.
Claim or correct this profile